The cost of the initiative is estimated at $20 million. It is implemented by the V-Gen Biopharma company, created by Jurabek Laboratories and the Tashkent Research Institute of Vaccines and Serums.

A feasibility study for the project will be developed in the first quarter of this year, and they want to start production as early as 2023.

Now, the Jurabek Laboratories plant in Almalyk produces two vaccines against coronavirus – the Russian Sputnik V and the Chinese-Uzbek ZF-UZ-VAC 2001.